ALEXANDRIA, Va. – August 27, 2020 – Buchanan Ingersoll & Rooney’s Intellectual Property practice has been ranked in multiple categories in the 2020 Patexia ANDA (Abbreviated New Drug Application) Litigation Intelligence Report. Specifically, the practice is ranked the categories of Most Active Law Firm (Defendant); Most Active Law Firm (Overall), Best Performing Firm (Defendant) and Best Performing Firm (Overall).
“As a firm with a strong focus on the life sciences industry, we are proud that Patexia has recognized our firm and Intellectual Property practice among the top firms representing companies in Hatch-Waxman/ANDA matters.” said Lloyd Smith, shareholder and IP Litigation group chair.
“The seamless integration between our litigators, FDA regulatory attorneys and intellectual property practice gives us the depth to handle any issue encountered in Hatch-Waxman litigation and is not commonly found among law firms,” added Matthew L. Fedowitz, shareholder in the IP section who focuses on the life sciences industry.
Buchanan’s IP Litigation team brings together a multidisciplinary team with backgrounds in many branches of pharmaceutical and biological sciences. We represent some of the world’s most respected brand and generic pharmaceutical companies in dozens of high-stakes Paragraph IV cases for blockbuster drugs as well as niche drugs with smaller markets at every stage of product development.
Patexia evaluated over 240 law firms and 1,105 attorneys (including ANDA local counsel) based on activity and performance over a period from June 2017 through June 2020. The results were measured and verified by an independent third-party. The study took into consideration:
- 976 ANDA Cases
- 1,328 Patents
- 1,105 Attorneys (Lead and Local Counsel)
- 240 Law Firms
- 320 Pharmaceutical Companies
- 97 Judges